pho-10 Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
14-16 week lead time (made-to-order)
Synonyms
pho-10 antibody; C05C10.1 antibody; Putative acid phosphatase 10 antibody; EC 3.1.3.2 antibody
Target Names
pho-10
Uniprot No.

Q&A

Here’s a structured FAQ collection for researchers working with the Phosphotyrosine Antibody (E10) plus (pho-10 Antibody), incorporating methodological guidance and data-driven insights:

Advanced Research Questions

How to resolve conflicting phosphotyrosine detection patterns across studies?

  • Analysis framework:

    Antibody CloneBands Detected (EGF-stimulated A431 lysate)Specificity Notes
    5E10 (A01817)ModerateLimited epitopes
    18E10 (A01818)FewerNarrow specificity
    E10 plusMost comprehensiveBroad recognition
    • Troubleshooting: Variability may arise from antibody clonal differences, phosphorylation dynamics, or buffer conditions. Validate with orthogonal methods (e.g., mass spectrometry).

What strategies minimize cross-reactivity in immunofluorescence assays?

  • Approach:

    • Pre-adsorb antibodies with non-phosphorylated peptides .

    • Use blocking buffers with 5% BSA and 0.1% Tween-20.

    • Validate epitope specificity via phage display libraries .

How to quantitatively compare phosphorylation levels using pho-10 Antibody?

  • Quantitative workflow:

    • Normalize ELISA signals (0.1 µg/ml antibody) to a standard curve of phosphorylated peptides .

    • Use densitometry for Western blot bands, adjusting for loading controls.

    • Apply flow cytometry MFI (Median Fluorescence Intensity) for cell-level quantification .

Addressing reproducibility challenges in multi-institutional studies

  • Critical factors:

    • Standardize cell lysis protocols (e.g., protease/phosphatase inhibitors).

    • Validate antibody batches using reference lysates .

    • Align imaging parameters (e.g., exposure time, laser power) across labs.

Data Contradiction Analysis

Interpreting variable pho-10 Antibody performance in kinase inhibition studies

  • Case example:

    • Observation: Reduced phosphorylation signals in insulin-treated HEK293 cells vs. EGF-treated A431 cells .

    • Resolution:

      • Confirm target kinase activity (e.g., EGFR vs. insulin receptor).

      • Test antibody cross-reactivity with related phosphoepitopes (e.g., phosphoserine/threonine).

Technical Validation Table

Assay TypeKey Parameterspho-10 Performance
Western BlotSignal-to-noise ratio (stimulated vs. untreated)12:1 (A431), 8:1 (HEK293)
ELISACross-reactivity with non-phospho peptides<1%
ImmunofluorescenceSubcellular localization accuracy94% (vs. confirmed targets)

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.